May 5, 2004, Baltimore, MD — Cognis Nutrition and Health, a global leader in the manufacture and innovation of nature-based ingredients and application technology for health and food products, is realigning its marketing strategy to focus on product concepts that support three of the most pressing areas of human health: heart health, eye health, and body composition.
“Consumers leading busy lives require intelligent solutions that are based on the most up-to-date scientific evidence, presented with clear solutions and claims,” said Cognis’ Kathleen Moran, Global Market Segment Manager, Dietary Supplements, during the SupplySide East tradeshow and conference in Baltimore, MD. “Cognis recognizes this growing consumer trend for supplements formulated to address specific health concerns. Helping our customers create innovative formulations to address these health concerns, and then creatively market them, is our primary focus,” Ms. Moran explained.
In the longer term, Cognis will be looking at blends to patent for scientifically proven products, working with Research & Development and ingredient companies to bring these products to market.
Cognis Nutrition & Health offers an extensive portfolio of natural-source ingredients for dietary supplements and functional foods targeted at these three aspects of health:
Heart Health (VEGAPURE® Vegetable Sterol Esters)
To help customers evaluate products for heart health, Cognis’ Kathleen Moran, Global Market Segment Manager, Dietary Supplements, and Laura Brennan, Marketing Manager, presented a session on “Healthy Formulations to Meet the Growing Demand for Cholesterol-Lowering Products" at SupplySide East. Ms. Moran and Brennan highlighted research news, regulatory updates and new marketing data. In a review of over 10 cholesterol-lowering ingredients, they evaluated efficacy, allowable claims and cost per dose against Cognis' exacting standards. “We were gratified to learn that our VEGAPURE® is leading the pack, based on claims and evidence, but there are other ingredients that are strong as well. We shared this analysis, pointing out areas where the science behind some ingredients is stronger in some cases than in others. Our intent is to raise the bar for setting standards and evaluating these products,” Ms. Moran said.
Cognis is the world’s leading producer of sterol esters and the longest-standing supplier of natural vitamin E products. In addition to VEGAPURE® for heart health, Cognis offers one of the industry’s most extensive lines of COVITOL® natural vitamin E and COVI-OX® natural mixed tocopherols ingredients.
Eye Health (XANGOLD® Natural Lutein Esters and Betatene® Natural Mixed Carotenoids)
Cognis has petitioned the Federal Food and Drug Administration (FDA) for a qualified health claim (QHC) linking consumption of XANGOLD® Natural Lutein Esters to reduced risk of two major eye diseases: age-related macular degeneration (AMD) and cataracts. The FDA has slated the QHC (2004Q-0180) for review and is expected to respond to Cognis’ petition within eight months (http://www.fda.gov/ohrms/dockets/dockets/04q0180/04q0180.htm). The proposed petition states: “Consumption of 12 mg XANGOLD lutein esters per day may reduce the risk of Age-related Macular Degeneration (AMD) and cataract formation. FDA has determined that the evidence is supportive, but not conclusive, for this claim. (This food/dietary supplement) provides _ mg lutein esters per serving).”
AMD and cataracts are the leading causes of visual loss and blindness in the U.S., affecting millions of aging Americans. Fortunately, carotenoids found in XANGOLD® Natural Lutein Esters are showing promise to help prevent these diseases. Research has shown that lutein and zeaxanthin, the only carotenoids found in the retina and lens of the eye, may act as antioxidants and filters to protect the eye from oxidative damage over a lifetime of exposure to harmful light. XANGOLD® natural lutein esters are an excellent, bioavailable source of lutein.
“This qualified health claim is a critical step forward to assist consumers as they search for effective, safe and affordable eye health products that contain XANGOLD®,” said Carrie Potaczek, Cognis’ Product Manager for XANGOLD® Natural Lutein Esters. Cognis strongly believes that, based on the compelling science supporting lutein esters, significant public health benefits will result from this qualified health claim once it’s approved. “We expect to contribute not only an improvement in the declining vision of our aging population, but also to have a beneficial impact on sky-rocketing health care costs,” Ms. Potaczek explained.
With this pending qualified health claim, interest in XANOLD® Natural Lutein Esters is expected to build on its success following Cognis’ completion of the FDA’s Generally Recognized As Safe (GRAS, GRN #110) notification process, paving the way for its use in a broad range of foods.
Other products Cognis offers for eye health include BETATENE® Natural Mixed Carotenoids and a complete line of COVITOL® natural vitamin E ingredients.
Body Composition (TONALIN® Conjugated Linoleic Acid)
Cognis recently announced that its TONALIN® (Tôn-a-lin) brand of CLA (Conjugated Linoleic Acid) had been self-affirmed as Generally Recognized As Safe (GRAS) by a panel of independent experts. Cognis now offers the food industry one of the most extensive lines of CLA ingredients available for a broad range of approved food applications.
TONALIN®, the #1 consumer brand of CLA, is intended to help consumers reduce body fat, maintain lean body mass, prevent fat regain and contribute to improved overall health.
A panel of independent experts has found that TONALIN® is safe for use in yogurt, meal replacement bars and drinks, fruit juices, chocolate, milk-based beverages and coffee cream substitutes. Cognis asked this panel to evaluate research conducted with TONALIN® to determine its safety for use in food products.
“TONALIN® is already the most recognized brand of CLA, and now with it achieving self-affirmed GRAS status, it should be the ingredient of choice for food manufacturers wanting to market safe and effective products targeted at consumers to help them improve their body composition,” said Scott Backman, Cognis’ Market Development Manager—Functional Food and Food Technology. “This new ingredient for food could help revolutionize the way people reduce body fat. We expect the high level of consumer awareness for the TONALIN® brand to grow even more as a result of national radio and print advertising campaigns, widespread media coverage, and in-store promotions,” Mr. Backman explained.
Heather Nelson Cortes, PhD, who heads Cognis’ global science program for TONALIN®, said, “The majority of all published, CLA clinical research has been done with TONALIN® CLA. Seven clinical studies published within the last four years, within peer-reviewed journals, all indicate significant improvement in at least one body composition measurement with TONALIN® CLA.” She explained that TONALIN® CLA has been clinically proven to aid in the maintenance of lean tissue and may help tone the body without necessarily causing overall weight loss.
Cognis produces TONALIN® CLA through a new proprietary process that converts linoleic acid from safflowers into CLA which provides the highest quality of CLA available. TONALIN® CLA contains the lowest amount of non-naturally occurring isomers, a patent-protected attribute that provides food manufacturers with the highest levels of ingredients known to be beneficial.
For more information about Cognis’ health enhancing products, visit www.Cognis.com and click on Nutrition & Health.
Cognis (www.Cognis.com) is a worldwide supplier of innovative specialty chemicals and nutritional ingredients. It employs 8,600 people, and has production sites and service centers in almost 30 countries. The company has dedicated its activities to a high level of sustainability and delivers natural source raw materials and ingredients for food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries. Additionally, Cognis provides solutions for a number of other industries, such as coatings and inks, lubricants, textiles and plastics, as well as agriculture and mining. Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and Schroder Ventures Life Sciences. In 2003, Cognis recorded sales of 2.95 billion euros and an operating profit before depreciation, amortization and exceptional items (EBITDA recurring) of 312 million euros.